What is the recommended protocol for newborn screening of rare metabolic, endocrine, hematologic, and immunologic disorders?

Newborn Screening for Rare Disorders

All newborns should undergo comprehensive screening using tandem mass spectrometry (MS/MS) for at least 29 core metabolic, endocrine, hematologic, and immunologic disorders, with mandatory reporting of secondary target conditions and systematic confirmatory testing protocols for positive results. 1

Core Screening Protocol

Initial Screening Requirements

• Collect dried blood spot samples from all newborns, typically between 24-48 hours after birth, using standardized filter paper 1, 2
• Screen for the 29 core panel conditions mandated by the American College of Medical Genetics (ACMG), which include metabolic disorders detectable by tandem mass spectrometry, congenital hypothyroidism, congenital adrenal hyperplasia, hemoglobinopathies, and severe combined immunodeficiency 1
• Utilize tandem mass spectrometry as the primary technology for detecting amino acid disorders, organic acid disorders, and fatty acid oxidation defects in a single analysis 1, 3

Disorders Requiring Mandatory Screening

The core panel includes conditions across multiple categories 1, 2:

• Amino acid disorders: Phenylketonuria (PKU), maple syrup urine disease, homocystinuria, citrullinemia, argininosuccinic aciduria 1, 4
• Organic acid disorders: Propionic acidemia, methylmalonic acidemia, isovaleric acidemia, glutaric acidemia type I 1, 3
• Fatty acid oxidation disorders: Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency 1, 2
• Endocrine disorders: Congenital hypothyroidism, congenital adrenal hyperplasia 1, 4
• Hemoglobinopathies: Sickle cell disease and variants 1
• Other disorders: Galactosemia, biotinidase deficiency, cystic fibrosis 2, 4

Confirmatory Testing Protocol for Positive Screens

Immediate Actions for Out-of-Range Results

Contact the primary care provider and designated specialist by telephone first, followed by written notification, without delay 1

The notification must include 1:

• Newborn's identifying information (name, date/time of birth, place of birth)
• Parent contact information
• Date and time of specimen collection
• Specific analytes evaluated and abnormal results with measurement units
• Normal ranges and cutoff values adjusted for gestational age and birth weight
• Required immediate actions with specific timelines

Disorder-Specific Confirmatory Testing

The diagnostic workup varies by disorder and must go beyond simple metabolite confirmation for most conditions 1:

• For disorders requiring only metabolite confirmation: Congenital hypothyroidism, maple syrup urine disease, propionic acidemia, argininosuccinic lyase deficiency, homocystinuria 1
• For disorders requiring enzyme or mutation analysis: VLCAD deficiency, LCHAD deficiency, SCAD deficiency, 3-methylcrotonyl-CoA carboxylase deficiency 1
• For PKU: Must rule out biopterin synthesis defects even though PKU has been screened for 45+ years 1

Comprehensive Diagnostic Evaluation

Refer all screen-positive infants to a specialty metabolic center for 1:

• Repeat acylcarnitine profile or amino acid analysis
• Organic acid analysis when indicated
• Enzyme activity assays for specific disorders
• Molecular genetic testing (mutation analysis) for definitive diagnosis
• Clinical and nutritional evaluation

Avoid "metabolite diagnoses" where infants have persistently abnormal metabolites but lack complete confirmatory testing, as this leads to incorrect diagnoses, inappropriate treatment, and flawed long-term outcome data 1

Critical Pitfalls to Avoid

False-Positive Management

• Recognize that positive predictive value can be as low as 10%, meaning for every true case, 9-12 additional infants receive false-positive results 1, 5
• Approximately 3% of all screened samples require repeat testing, mostly for mildly elevated results that resolve as normal 1
• Communicate results carefully to parents, explaining what initial findings mean even before diagnosis is confirmed, to minimize anxiety while ensuring appropriate follow-up 5

Secondary Target Conditions

Mandate reporting of all 25 secondary target conditions identified through differential diagnosis of core panel disorders, even when clinical significance is uncertain 1

These include 1:

• SCAD deficiency
• 3-methylcrotonyl-CoA carboxylase deficiency
• Isobutyryl-CoA dehydrogenase deficiency
• Conditions that may represent benign variants or gene polymorphisms

Quality Assurance Requirements

Implement systematic long-term follow-up (LTFU) for all diagnosed patients to 1:

• Collect clinical outcome data to refine screening cutoff values
• Determine whether mild phenotypes constitute true disease versus benign metabolic variants
• Reduce false-positive rates over time while maintaining extremely low false-negative rates
• Enable evidence-based refinement of screening algorithms

System-Level Implementation

Laboratory Standards

• Use dried blood spot calibrators and controls prepared on identical filter paper lot numbers 2
• Accept coefficient of variation of approximately 10% due to inherent variability of dried filter paper samples 2
• Establish cutoff values balancing sensitivity and specificity, recognizing few assays achieve 100% discrimination 2

Reporting and Oversight

• Standardize case definitions and reporting procedures across all screening programs 1
• Obtain confirmatory test results from specialty centers and feed back to screening laboratories 1
• Enhance hospital-based screening oversight to improve tracking of screen-positive cases 1
• Ensure insurance coverage for expensive confirmatory tests by following acknowledged specialist guidelines 1

Resources for Providers

Utilize ACMG ACTion sheets and algorithms for immediate guidance on responding to abnormal results 1, 5

Access GeneTests database to identify laboratories performing specific confirmatory analyses 1